Ultra-small coordination dihydromyricetin nanodots attenuate alveolar bone resorption in periodontitis through inhibition of ITGB3-Driven osteoclast differentiation.

ABSTRACT: Irreversible alveolar bone resorption induced by periodontitis constitutes a major etiological factor in adult tooth loss, with its underlying pathological mechanism tightly linked to dysregulated osteoclast differentiation. Conventional clinical interventions for alveolar bone resorption, such as basic periodontal therapy and surgical procedures, are limited in their capacity to effectively inhibit osteoclast differentiation. Dihydromyricetin (DMY), a naturally derived flavonoid compound, exhibits promising inhibitory activity against osteoclast differentiation; however, its poor aqueous solubility and suboptimal bioavailability following localized administration hinder its therapeutic potential. To address these limitations, this study developed ultra-small coordination nanodots (DMY-NDs

SUBMITTER: Zhao B 

PROVIDER: S-EPMC12639494 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature